CJC-1295 wihtout DAC (5mg)

Advanced peptide for controlled growth hormone research applications.

• CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH 1–29).
• Studied in pre-clinical settings for its ability to stimulate growth hormone release and modulate IGF-1 levels in research models.
• Independently verified for purity and sequence integrity by Vanguard Laboratory.

CJC-1295 is a tetra-substituted peptide analog of GHRH with an extended half-life, designed to promote sustained growth hormone (GH) release via pituitary stimulation

In controlled studies, CJC-1295 has demonstrated increased pulsatile GH secretion and elevated circulating IGF-1 concentrations through binding affinity to GHRH receptors

Regulatory Status: CJC-1295 is not FDA-approved for human or veterinary use and is provided strictly for laboratory research purposes.